Researchers identify enzyme that suppresses immune system in breast cancer

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a small number of patients are even eligible to undergo treatment with immunotherapies, and most see little benefit.

But in a pre-clinical study led by the Duke Cancer Institute, researchers outlined a potential way to improve those results by uncloaking breast cancer tumors to the body's immune system.

Publishing this month in the journal Nature Communications, the researchers identified an enzyme in cells involved in regulating the growth and spread of breast cancers. Testing in mice, they demonstrated a way to shut down the enzyme's activity to allow T-cells to mount an immune attack.

"We found that inhibition of the activity of this enzyme decreased the ability of macrophages in tumors to suppress an immune attack on cancer cells and indeed encouraged them to start producing chemicals that attract more cancer-killing T cells into the tumor," said Donald McDonnell, Ph.D., chair of Duke's Department of Pharmacology & Cancer Biology. "We can basically uncloak the tumor to the immune system."

McDonnell and colleagues, including lead author and collaborator Luigi Racioppi, M.D., Ph.D., reported that a kinase, or enzyme, called CaMKK2 is highly expressed in macrophages within human breast tumors. They performed a series of exploratory studies that revealed the molecule's potential utility as a therapeutic target for breast cancer. Working with colleagues at the University of North Carolina at Chapel Hill, they developed a new class of drugs that inhibited the growth of human breast tumors grown in mice.

"The use of this molecule suppressed tumor growth not only by increasing the accumulation of tumor-killing T cells, but also by reducing the tumor's capability to suppress T cell activity," McDonnell said. "It's solving two problems, like we couldn't get into the bar, and if we did, we couldn't get a drink. Now we can do both."

McDonnell said additional studies are ongoing, with the goal of acquiring data to launch a clinical trial in breast cancer patients within the next 18 months.

Luigi Racioppi, Erik R Nelson, Wei Huang, Debarati Mukherjee, Scott A Lawrence, William Lento, Anna Maria Masci, Yiquin Jiao, Sunghee Park, Brian York, Yaping Liu, Amy E Baek, David H Drewry, William J Zuercher, Francesca R Bertani, Luca Businaro, Joseph Geradts, Allison Hall, Anthony R Means, Nelson Chao, Ching-yi Chang, Donald P McDonnell.
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
Nature Communications 10, Article number: 2450 (2019). doi: 10.1038/s41467-019-10424-5.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...